en · de · es
analytical-notes.peptides5388.com › Data › Sr9009 Background And Receptor Mechanism — Research Overview

Sr9009 Background And Receptor Mechanism — Research Overview

By Editorial Desk · published 2026-07-20 · last reviewed 2026-08-01 · Data

A practical reference on REV-ERB agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.

SR9009 Background and Receptor Mechanism

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule nuclear receptor ligand
AppearanceOff-white to pale yellow solidTypical for research-grade powder
Solubility classSoluble in DMSO; low water solubilityCommon stock solutions use organic solvent
Typical stock solventDimethyl sulfoxideUsed for laboratory assays
Common analytical methodHPLC with UV or mass detectionUsed for identity and purity checks

SR9009 Handling and Quality Control

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Related pages on this site

Detection, Regulation, and Misconceptions

Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Background from the literature

n RCHNHC(O)OC(O) → [N(H)CH(R)CO)]n + n CO2 Poly-L-lysine has been prepared from N-carbobenzyloxy-α-N-carboxy-L-lysine anhydride, followed by deprotection with phosphonium iodide. Peptide synthesis from NCAs does not require protection of the amino acid functional groups. N-Substituted NCAs, such as sulfenamide derivatives have also been examined. The ring-opening polymerization of NCAs is catalyzed by metal catalysts. The polymerization of NCA’s have been considered as a prebiotic route to polypeptides. NCAs can also be used to form amides and lactams by reaction of carboxylic acids and isocyanates. Dakin–West reaction Glycine N-carboxyanhydride, the parent NCA

All actinides are radioactive and release energy upon radioactive decay; naturally occurring uranium and thorium, and synthetically produced plutonium are the most abundant actinides on Earth. These have been used in nuclear reactors, and uranium and plutonium are critical elements of nuclear weapons. Uranium and thorium also have diverse current or historical uses, and americium is used in the ionization chambers of most modern smoke detectors. Due to their long half-lives, only thorium and uranium are found on Earth and astrophysically in substantial quantities. The radioactive decay of uranium produces transient amounts of actinium and protactinium, and atoms of neptunium and plutonium are occasionally produced from transmutation reactions in uranium ores. The other actinides are purely synthetic elements. Nuclear weapons tests have released at least six actinides heavier than plutonium into the environment; analysis of debris from the 1952 first test of a hydrogen bomb showed the presence of americium, curium, berkelium, californium, and the discovery of einsteinium and fermium. In presentations of the periodic table, the f-block elements are customarily shown as two additional rows below the main body of the table. This convention is entirely a matter of aesthetics and formatting practicality; a rarely used wide-formatted periodic table inserts the 4f and 5f series in their proper places, as parts of the table's sixth and seventh rows (periods).

==== Switzerland ==== While THC remains illegal, cannabidiol is not subject to the Swiss Narcotic Acts because it does not produce a comparable psychoactive effect. Cannabis products containing less than 1% THC can be sold and purchased legally.

=== Woodhouse Grammar School === After the First World War, the former residence of ornamental plasterer Thomas Collins (1735–1830) in the Woodhouse area of Finchley was reconstructed; the house became The Woodhouse School in 1923. A blue plaque commemorating Thomas Collins is on the wall outside the present college office. The school coat of arms with the motto 'Cheerfulness with Industry' is still displayed above the stage in the college hall. During the Second World War, the school continued to function while the basement was used by the ARP service. The names of the forty-seven former pupils who died during WWII are recorded in a hand-illuminated Roll of Honour which hangs at the foot of the main staircase near the front entrance to the college. The Roll of Honour also records the names of the four houses of the old grammar school: Gordon, Livingstone, Nightingale and Scott.

Sources: en.wikipedia.org

Further detail

=== Post-war === At the end of the war the British government saw no further need for the force and disbanded it on 8 October 1945. The following year it was decided there was a need for a long-term deep-penetration commando unit and a new SAS regiment was to be raised as part of the Territorial Army. Ultimately, the Artists Rifles, raised in 1860 and headquartered at Dukes Road, Euston, took on the SAS mantle as 21st SAS Regiment (V) on 1 January 1947. John Woodhouse was chosen to assist with establishing a reformed selection process for the SAS. The rigorous systems he assisted in developing over three years provided the basis of selection and training of the modern SAS.

== Interactions == GPX1 has been shown to interact with ABL and GSH. A recently discovered suppressor for GPX1 is S-adenosylhomocysteine, which when accumulated in endothelial cells can cause tRNA(Sec) hypomethylation, reducing the expression of GPX1 and other selenoproteins. The decreased GPX-1 expression can then lead to inflammatory activating of endothelial cells, helping give rise to a proatherogenic endothelial phenotype.

==== MeSH E05.478.567 – immunoassay ==== MeSH E05.478.567.320 – immunoblotting MeSH E05.478.567.320.200 – blotting, western MeSH E05.478.567.320.200.200 – blotting, far-western MeSH E05.478.567.350 – immunoenzyme techniques MeSH E05.478.567.350.170 – enzyme-linked immunosorbent assay MeSH E05.478.567.350.180 – enzyme multiplied immunoassay technique MeSH E05.478.567.380 – immunosorbent techniques MeSH E05.478.567.380.360 – enzyme-linked immunosorbent assay MeSH E05.478.567.380.810 – radioallergosorbent test MeSH E05.478.567.380.825 – radioimmunoprecipitation assay MeSH E05.478.567.380.830 – radioimmunosorbent test MeSH E05.478.567.639 – radioimmunoassay MeSH E05.478.567.639.405 – immunoradiometric assay MeSH E05.478.567.639.810 – radioallergosorbent test MeSH E05.478.567.639.825 – radioimmunoprecipitation assay MeSH E05.478.567.639.830 – radioimmunosorbent test

=== Amide bond formation === Most commonly 2,5-diketopiperazines are generated by cyclisation of dipeptides. In addition to the many methods of peptide synthesis, the Ugi reaction can be applied. Dipeptides with an ester terminus spontaneously cyclize often. Racemization can be problematic. The Ugi reaction using an isonitrile, amino acid, aldehyde and amine, can produce a dipeptide in equally high yield and optical purity, to that formed by standard peptide couplings. Commonly, an isonitrile is chosen to give a labile terminal amide to enable cyclization. For example, the direct 2,5-DKP ring formation via such an activated leaving group using the stable, easily accessible and versatile convertible isonitrile 1-isocyano-2-(2,2-dimethoxyethyl)-benzene 4 gave a one-pot synthesis of N-substituted 2,5-diketopiperazine's 7.

==== Methadone ==== Methadone is a commonly used full-opioid agonist in the treatment of opioid use disorder. It is effective in relieving withdrawal symptoms and cravings in people with opioid addiction, and can also be used in pain control in certain situations. While methadone is a widely prescribed form of OAT, it often requires more frequent clinical visits compared to buprenorphine/naloxone, which also has a better safety profile and lower risk of respiratory depression and overdose. Important considerations when initiating methadone include the patient's opioid tolerance, the time since last opioid use, the type of opioid used (long-acting vs. short-acting), and the risk of methadone toxicity. Methadone comes in different forms: tablet, oral solution, or an injection. One of methadone's benefits is that it can last up to 56 hours in the body, so if a patient misses a daily dose, they will not typically struggle with withdrawal symptoms. Other advantages of methadone include reduction in infectious disease related to injection drug use, and reduced mortality. Methadone has a number of potential side effects, including slowed breathing, nausea, vomiting, restlessness, and headache.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.

How does SR9009 work?

It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.

Is SR9009 a proven performance enhancer?

No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Network